Skip to Content

Collaborative R&D project

OncoImmuNEX

Preclinical validation of a completely animal-free platform for synthetic nano-antibodies (VHH binders) in oncology.

Coordinator Ymolution GmbHPartner University Medicine Greifswald

Aim of the collaborative project

From proof of concept to preclinical drug candidates.

The overarching aim of the collaborative R&D project OncoImmuNEX is the first systematic application and preclinical validation of a novel, completely animal-free technology platform for the generation of synthetic nano-antibodies (VHH binders). The project thereby takes the decisive step from technological proof of concept to the structured development of specific preclinical drug candidates for oncology.

The focus is on overcoming a fundamental barrier of classical antibody development: the homology problem. Many oncologically relevant target structures are highly conserved in evolutionary terms, which means that classical animal-based immunization platforms (e.g., in camelids or rodents) regularly fail. Because of immunological tolerance mechanisms, such structures are recognized as self, which prevents an efficient immune response. OncoImmuNEX addresses this limitation with a fully synthetic in vitro platform that works independently of biological immune mechanisms and thus enables the targeted generation of functional VHH binders against highly conserved human epitopes.

Beyond technological validation, the project pursues a strategic aim geared directly toward commercialization: the development of two highly relevant oncological drug candidates that will constitute the first therapeutic assets in Ymolution GmbH’s proprietary pipeline and that will be moved into direct commercial exploitation after the project ends (e.g., through out-licensing, strategic co-development or preparation of early clinical development stages). The underlying target structures originate from current translational research programs at University Medicine Greifswald and therefore show high clinical and pathophysiological relevance.

At the same time, these two development tracks serve as a complementary proof of performance for the platform technology. They therefore not only serve target validation, but also systematically demonstrate the platform’s capability to develop therapeutically usable drug candidates under real-world development conditions.

Two complementary development tracks

Validation on two oncological targets.

Extracellular: surface target FCRL2

  • Medical objectiveThe surface antigen FCRL2 shows tumor-specific expression on malignant B cells (e.g., in certain leukemias and lymphomas). To date, no therapeutically established antibody solutions with sufficient functional specificity and development maturity are available for FCRL2.
  • Project objectiveDevelopment and functional ex vivo characterization of a high-affinity nano-antibody lead candidate. It serves as the biological starting format for cell-based immunotherapies (such as CAR T cells) or bispecific antibody formats.

Intracellular: nuclear target BCL11B

  • Medical objectiveThe transcription factor BCL11B is a central regulator of T cell identity and is severely dysregulated in the context of hematological neoplasms. Because of its intracellular localization, BCL11B is considered a therapeutically hard-to-access "high-risk target".
  • Project objectiveThe de novo generation of functional VHH binders that are transported into the cell interior by means of innovative delivery strategies in order to achieve targeted reduction or functional modulation of the oncogene.

Subprojects

Platform technology meets translational oncology.

The collaborative project is divided into two complementary individual projects that combine a novel, proprietary technology platform with leading academic research in translational oncology.

Individual project: Ymolution GmbH

Ymolution GmbH is responsible for the generation, selection and initial characterization of all nano-antibody candidates against FCRL2 and BCL11B (WP 1). Based on the Ymolution platform technology, epitope-based target and antigen formats are defined, library screens are carried out, and functional lead candidates are identified in iterative selection and validation cycles. The selected candidates are expressed recombinantly, purified and characterized biophysically and functionally with respect to binding affinity, stability and initial target selectivity.

In addition, Ymolution takes on an overarching supporting role in the other work packages of the consortium and ensures the iterative further development of the nano-antibodies in line with the experimental requirements. This includes in particular their adaptation and formatting as needed for downstream validation stages, including ex vivo validation, as well as their integration into suitable delivery and fusion systems. For this purpose, required modifications such as tags, fusion domains or conjugation strategies are implemented in order to ensure compatibility with the respective test systems.

Alongside this, Ymolution is responsible for preparing and adapting the format of the nano-antibodies for all downstream test systems, as well as for the consortium’s IP, commercialization and regulatory strategy (WP 6). This includes identifying protectable results, coordinating patent applications, and aligning the development and manufacturing processes at an early stage with the requirements of the European In Vitro Diagnostic Regulation.

Individual project: University Medicine Greifswald

The UMG individual project combines the complementary expertise of two research groups and addresses independent scientific questions in the fields of structural proteomics and intracellular drug targeting.

Within WP 3, the Völker group (Institute of Genetics and Functional Genomics) is establishing an HDX-MS-based analytical platform for high-resolution structural characterization of protein-protein and antigen/nano-antibody interactions. Binding regions, conformational dynamics and stability properties are analyzed under physiologically relevant conditions. The method allows precise epitope mapping, which supports the targeted optimization of the lead candidates. In WP 4, the group also carries out the functional comparison of the delivery strategies developed in WP 2 under defined experimental conditions and assesses them in terms of intracellular delivery efficiency, target protein modulation and reproducibility. In WP 2, the Krönke group (Department of Internal Medicine C) is developing two complementary delivery strategies for the intracellular delivery of BCL11B-directed nano-antibodies: an endogenous strategy via mRNA or lentiviral vector systems, and an exogenous, conditionally controllable degradation strategy. WP 5 finally covers the ex vivo validation of the FCRL2-specific nano-antibodies in patient-derived primary cell models, examining target binding, interaction stability and functional effects on FCRL2-expressing cells under physiologically relevant conditions. The group has an extensive biobank of clinically and genetically characterized patient samples as well as established cell models and ex vivo test systems.

Collaboration within the consortium

The entire development chain in one consortium.

Contact for further information: info@ymolution.com

Collaboration within the OncoImmuNEX consortium is designed for close coordination of the subprojects in both content and timing. As the central technology partner, Ymolution GmbH successively provides the nano-antibody candidates generated in WP 1 for all downstream work packages. Conversely, UMG is involved in target selection and early proteomic characterization from the start of the project and actively shapes the selection strategy, so that the candidates developed are tailored to the specific analytical and clinical requirements from the outset.

The structural characterization by the Völker group (WP 3) provides direct feedback for the iterative optimization of the candidates by Ymolution and forms the basis for the ex vivo validation in WP 5. The delivery strategies developed by the Krönke group in WP 2 likewise use the nano-antibodies provided by Ymolution and feed into the comparative benchmarking in WP 4, in which both UMG groups and Ymolution participate. The IP and ethics strategy in WP 6 is coordinated across partners: Ymolution is responsible for the overall intellectual property strategy, while UMG ensures that the ethics approvals required for the patient-derived investigations are obtained.

The institutional basis for cooperation is particularly close and stable thanks to the participation of University Medicine Greifswald as a minority shareholder in Ymolution GmbH. This provides contractual structures for access to highly specialized infrastructure as well as a shared interest in the translational commercialization of the project results. The combination of Ymolution GmbH’s innovative nano-antibody platform with UMG’s methodological depth and clinical access creates a consortium that fully covers the entire development chain from molecular generation to patient-derived validation and deliberately builds the prerequisites for industrial and therapeutic follow-on development of the drug candidates.